Eli Lilly and Company (SNSE:LLYCL)

Market Cap	834.89T
Revenue (ttm)	57.14T
Net Income (ttm)	17.71T
Shares Out	n/a
EPS (ttm)	19,657.33
PE Ratio	47.15
Forward PE	32.00
Dividend	5,662.59 (0.58%)
Ex-Dividend Date	Nov 14, 2025

Volume	n/a
Average Volume	135
Open	n/a
Previous Close	976,480
Day's Range	n/a
52-Week Range	608,400 - 1,034,500
Beta	n/a
RSI	65.25
Earnings Date	Feb 6, 2026

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja...

• Industry: Pharmaceutical Preparations
• Founded: 1876
• Employees: 47,000
• Stock Exchange: Santiago Stock Exchange
• Ticker Symbol: LLYCL

Financial Performance

In 2024, Eli Lilly and Company's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.

Financial numbers in USD